ARROWHEAD PHARMACEUTICALS, INC.ARWREarnings & Financial Report
Arrowhead Pharmaceuticals, Inc. is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead's products in development act through RNA interference (RNAi) mechanisms of action. The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular disease.
ARWR Q1 2026 Key Financial Metrics
Revenue
$264.0M
Gross Profit
N/A
Operating Profit
$40.8M
Net Profit
$30.8M
Gross Margin
N/A
Operating Margin
15.5%
Net Margin
11.7%
YoY Growth
10461.3%
EPS
$0.22
Financial Flow
ARROWHEAD PHARMACEUTICALS, INC. Q1 2026 Financial Summary
ARROWHEAD PHARMACEUTICALS, INC. reported revenue of $264.0M for Q1 2026, with a net profit of $30.8M (11.7% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $264.0M |
|---|---|
| Net Profit | $30.8M |
| Gross Margin | N/A |
| Operating Margin | 15.5% |
| Report Period | Q1 2026 |
ARROWHEAD PHARMACEUTICALS, INC. Annual Revenue by Year
ARROWHEAD PHARMACEUTICALS, INC. annual revenue history includes year-by-year totals (for example, 2025 revenue was $829.4M).
| Year | Annual Revenue |
|---|---|
| 2025 | $829.4M |
| 2024 | $3.6M |
| 2023 | $240.7M |
| 2022 | $243.2M |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $2.5M | $542.7M | $27.8M | $256.5M | $264.0M |
| YoY Growth | N/A | N/A | N/A | -29.6% | N/A | N/A | N/A | 10461.3% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $955.1M | $883.8M | $1.14B | $1.01B | $1.57B | $1.38B | $1.39B | $1.60B |
| Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Equity | $483.8M | $330.5M | $185.4M | $52.6M | $683.3M | $522.3M | $466.1M | $568.4M |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-92.4M | $-115.4M | $-137.2M | $-146.3M | $460.1M | $-154.7M | $20.5M | $13.5M |
More Companies
ILMN
ILLUMINA, INC.
Revenue
$1.2B
Net Profit
$334.0M
UTHR
UNITED THERAPEUTICS Corp
Revenue
$799.5M
Net Profit
$338.7M
GMAB
GENMAB A/S
Revenue
$925.0M
Net Profit
$336.0M
GH
Guardant Health, Inc.
Revenue
$265.2M
Net Profit
$-92.7M
NBIX
NEUROCRINE BIOSCIENCES INC
Revenue
$805.5M
Net Profit
$153.7M
EXEL
EXELIXIS, INC.
Revenue
$598.7M
Net Profit
$244.5M
MDGL
MADRIGAL PHARMACEUTICALS, INC.
Revenue
$287.3M
Net Profit
$-114.2M
QGEN
QIAGEN N.V.
BMRN
BIOMARIN PHARMACEUTICAL INC
Revenue
$776.1M
Net Profit
$-30.7M
BIO
BIO-RAD LABORATORIES, INC.
Revenue
$693.2M
Net Profit
$720.0M